Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer
Launched by THE NORWEGIAN LUNG CANCER STUDY GROUP · Aug 19, 2008
Trial Information
Current as of May 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Non-small cell lung cancer stage IIIB or IV
- • Not eligible for radical radiotherapy or surgery
- • WHO performance status 0-2
- Exclusion Criteria:
- • Pregnancy
- • Other clinical active cancer disease
- • ALAT/ALP more than 3 times upper normal limit, bilirubin \>1.5 upper limit
- • Bowel disease that causes malabsorption
About The Norwegian Lung Cancer Study Group
The Norwegian Lung Cancer Study Group is a collaborative network dedicated to advancing research and treatment in lung cancer through innovative clinical trials. Comprising leading experts in oncology, surgery, radiology, and pathology, the group focuses on improving patient outcomes by investigating novel therapeutic strategies, enhancing early detection methods, and fostering multidisciplinary approaches to care. By leveraging a robust framework of clinical collaboration and data sharing, the Norwegian Lung Cancer Study Group aims to contribute significantly to the global understanding of lung cancer and to drive evidence-based practice in the management of this challenging disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergen, , Norway
Haugesund, , Norway
Kristiansand, , Norway
Trondheim, , Norway
Patients applied
Trial Officials
Øystein Fløtten
Study Chair
Haukeland University Hospital, thoracic department
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials